应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
AVXL Anavex Life Sciences Corp.
交易中 09-30 13:27:06 EDT
2.16
-0.20
-8.47%
最高
2.38
最低
2.16
成交量
89.63万
今开
2.38
昨收
2.36
日振幅
9.32%
总市值
2.00亿
流通市值
1.97亿
总股本
9,267万
成交额
200.95万
换手率
0.98%
流通股本
9,112万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Pvg资产管理:Glass Lewis建议Avxl股东在2026年9月24日大会上投选金色通用代理卡
美股速递 · 09-18
Pvg资产管理:Glass Lewis建议Avxl股东在2026年9月24日大会上投选金色通用代理卡
PVG资产管理:Glass Lewis建议支持PVG候选人Hogue与Kolbert,反对现任董事Ma与Van Der Velden
美股速递 · 09-18
PVG资产管理:Glass Lewis建议支持PVG候选人Hogue与Kolbert,反对现任董事Ma与Van Der Velden
Pvg观点:Anavex现有团队恐难获取推进Blarcamesine 2B/3期试验所需资金
美股速递 · 09-09
Pvg观点:Anavex现有团队恐难获取推进Blarcamesine 2B/3期试验所需资金
Anavex Life Sciences 强调其高素质董事会及为股东创造长期价值的果断行动
美股速递 · 08-11
Anavex Life Sciences 强调其高素质董事会及为股东创造长期价值的果断行动
Anavex Life Sciences Corp 敦促股东否决PVG资产管理及Patrick S. Adams的控制企图
美股速递 · 08-03
Anavex Life Sciences Corp 敦促股东否决PVG资产管理及Patrick S. Adams的控制企图
Anavex Life Sciences Corp.宣布:Christopher Missling与Steffen Thomas将在2026年年度股东大会后离开董事会
美股速递 · 08-03
Anavex Life Sciences Corp.宣布:Christopher Missling与Steffen Thomas将在2026年年度股东大会后离开董事会
Anavex Life Sciences宣布董事会焕新计划,持续监督关键进展,力促股东价值创造
美股速递 · 08-03
Anavex Life Sciences宣布董事会焕新计划,持续监督关键进展,力促股东价值创造
Anavex生命科学董事会任命前临床开发高级副总裁Terrie Kellmeyer博士为临时首席执行官
美股速递 · 05-06
Anavex生命科学董事会任命前临床开发高级副总裁Terrie Kellmeyer博士为临时首席执行官
Anavex Life Sciences Corp.盘中异动 临近午盘股价大涨5.07%
市场透视 · 2025-03-10
Anavex Life Sciences Corp.盘中异动 临近午盘股价大涨5.07%
Anavex Life Sciences Corp.盘中异动 急速拉升5.12%
市场透视 · 2025-03-03
Anavex Life Sciences Corp.盘中异动 急速拉升5.12%
Anavex Life Sciences Corp.盘中异动 股价大涨5.05%
市场透视 · 2025-02-18
Anavex Life Sciences Corp.盘中异动 股价大涨5.05%
Anavex Life Sciences Corp.盘中异动 股价大涨5.37%报8.93美元
市场透视 · 2025-02-14
Anavex Life Sciences Corp.盘中异动 股价大涨5.37%报8.93美元
Anavex生命科学公司2025年第一季度GAAP每股收益$(0.14)好于预期$(0.19),截至2024年12月31日公司现金及现金等价物为1.208亿美元,按当前现金使用率和范围预计可维持约4年
财报速递 · 2025-02-12
Anavex生命科学公司2025年第一季度GAAP每股收益$(0.14)好于预期$(0.19),截至2024年12月31日公司现金及现金等价物为1.208亿美元,按当前现金使用率和范围预计可维持约4年
Anavex Life Sciences(AVXL.US):2025年Q1财报实现营收0美元,前值为0美元;每股收益为-0.14美元,前值为-0.11美元,预期值为-0.17美元。
金融界 · 2025-02-12
Anavex Life Sciences(AVXL.US):2025年Q1财报实现营收0美元,前值为0美元;每股收益为-0.14美元,前值为-0.11美元,预期值为-0.17美元。
Anavex Life Sciences Corp.盘中异动 股价大跌5.03%报8.37美元
市场透视 · 2025-02-11
Anavex Life Sciences Corp.盘中异动 股价大跌5.03%报8.37美元
Anavex Life Sciences Corp.盘中异动 早盘急速上涨5.09%
市场透视 · 2025-02-04
Anavex Life Sciences Corp.盘中异动 早盘急速上涨5.09%
Anavex Life Sciences Corp.盘中异动 急速下挫5.18%
市场透视 · 2025-02-03
Anavex Life Sciences Corp.盘中异动 急速下挫5.18%
Anavex Life Sciences Corp.盘中异动 股价大跌5.12%
市场透视 · 2025-02-01
Anavex Life Sciences Corp.盘中异动 股价大跌5.12%
Anavex Life Sciences Corp.盘中异动 早盘快速跳水5.19%报9.95美元
市场透视 · 2025-01-27
Anavex Life Sciences Corp.盘中异动 早盘快速跳水5.19%报9.95美元
Anavex Life Sciences Corp.盘中异动 股价大涨5.06%
市场透视 · 2025-01-24
Anavex Life Sciences Corp.盘中异动 股价大涨5.06%
加载更多
公司概况
公司名称:
Anavex Life Sciences Corp.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Anavex Life Sciences Corp.成立于2004年1月23日,位于内华达州。是一家临床阶段的生物制药公司,致力于开发差异化疗法,将精准医学应用于高度未满足需求的中枢神经系统(CNS)疾病。该公司的重点是开发针对阿尔茨海默病、帕金森病、精神分裂症、神经发育、神经退行性疾病、包括雷特综合征在内的罕见疾病以及其他中枢神经系统(CNS)疾病的创新疗法。
发行价格:
--
{"stockData":{"symbol":"AVXL","market":"US","secType":"STK","nameCN":"Anavex Life Sciences Corp.","latestPrice":2.16,"timestamp":1790789215377,"preClose":2.36,"halted":0,"volume":896347,"delay":0,"changeRate":-0.08474576271186429,"floatShares":91115856,"shares":92671758,"eps":-0.144583,"marketStatus":"交易中","change":-0.2,"latestTime":"09-30 13:27:06 EDT","open":2.38,"high":2.38,"low":2.16,"amount":2009506.6251909,"amplitude":0.09322,"askPrice":2.17,"askSize":1855,"bidPrice":2.16,"bidSize":1689,"shortable":3,"etf":0,"ttmEps":-0.144583,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1790798400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":2.36,"preHourTrading":{"tag":"盘前","latestPrice":2.37,"preClose":2.36,"latestTime":"09:25 EDT","volume":1,"amount":2.37,"timestamp":1790774700066,"change":0.01,"changeRate":0.004237,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":2.36,"preClose":2.36,"latestTime":"19:30 EDT","volume":3445,"amount":8130.59,"timestamp":1790724605596,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.5496,"impliedVol":0.9104,"impliedVolPercentile":0.2869},"requestUrl":"/m/hq/s/AVXL","defaultTab":"news","newsList":[{"id":"1195577128","title":"Pvg资产管理:Glass Lewis建议Avxl股东在2026年9月24日大会上投选金色通用代理卡","url":"https://stock-news.laohu8.com/highlight/detail?id=1195577128","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195577128?lang=zh_cn&edition=full","pubTime":"2026-09-18 00:21","pubTimestamp":1789662071,"startTime":"0","endTime":"0","summary":"Pvg资产管理公司发布声明称,Glass Lewis已正式建议Anavex Life Sciences Corp.的股东在即将于2026年9月24日召开的股东大会上,使用金色通用代理卡进行投票。Glass Lewis作为独立代理顾问机构,其意见在机构投资者群体中素有举足轻重的分量,往往能够左右关键选票的流向。Pvg资产管理对此建议表示欢迎,并强调此次投票对于公司未来发展路径至关重要。会议召开在即,时间紧迫,股东们需审慎权衡各方利弊,做出最符合自身利益的选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139762445","title":"PVG资产管理:Glass Lewis建议支持PVG候选人Hogue与Kolbert,反对现任董事Ma与Van Der Velden","url":"https://stock-news.laohu8.com/highlight/detail?id=1139762445","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139762445?lang=zh_cn&edition=full","pubTime":"2026-09-18 00:21","pubTimestamp":1789662070,"startTime":"0","endTime":"0","summary":"PVG资产管理公司近日披露,权威股东顾问机构Glass Lewis已正式表态——在即将到来的董事会改选中,建议投资者将票投给PVG提名的Hogue与Kolbert两位候选人。与此同时,该机构罕见地对现任董事会成员Ma及Van Der Velden投出了反对票。这一动向,无疑给这场本就备受关注的控制权之争,再添了一把火。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVXL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181050603","title":"Pvg观点:Anavex现有团队恐难获取推进Blarcamesine 2B/3期试验所需资金","url":"https://stock-news.laohu8.com/highlight/detail?id=1181050603","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181050603?lang=zh_cn&edition=full","pubTime":"2026-09-09 21:56","pubTimestamp":1788962169,"startTime":"0","endTime":"0","summary":"Pvg指出,他们认为Anavex Life Sciences Corp.难以凭借现有团队获取推动Blarcamesine 2B/3期临床试验所需的资金支持。这一判断直指公司当前面临的融资困境。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134981361","title":"Anavex Life Sciences 强调其高素质董事会及为股东创造长期价值的果断行动","url":"https://stock-news.laohu8.com/highlight/detail?id=1134981361","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134981361?lang=zh_cn&edition=full","pubTime":"2026-08-11 20:01","pubTimestamp":1786449691,"startTime":"0","endTime":"0","summary":"Anavex Life Sciences Corp.(简称:Anavex)近日着重强调,其董事会成员资质卓越,且公司已采取果断举措,旨在为股东构筑持久价值。这一系列行动,彰显了管理层对长期战略的坚定承诺与执行力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108657171","title":"Anavex Life Sciences Corp 敦促股东否决PVG资产管理及Patrick S. Adams的控制企图","url":"https://stock-news.laohu8.com/highlight/detail?id=1108657171","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108657171?lang=zh_cn&edition=full","pubTime":"2026-08-03 20:09","pubTimestamp":1785758958,"startTime":"0","endTime":"0","summary":"Anavex Life Sciences Corp(股票代码:AVXL)——这家生物科技公司正呼吁股东们,坚决抵制来自PVG资产管理公司及其负责人Patrick S. Adams的收购控制企图。公司管理层认为,该行动可能损害股东利益,并强调将采取一切必要措施,保护公司治理的独立性与长期价值主张。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191649706","title":"Anavex Life Sciences Corp.宣布:Christopher Missling与Steffen Thomas将在2026年年度股东大会后离开董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1191649706","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191649706?lang=zh_cn&edition=full","pubTime":"2026-08-03 20:04","pubTimestamp":1785758677,"startTime":"0","endTime":"0","summary":"Anavex Life Sciences Corp.(简称Anavex Life Sciences)近日披露一项重大人事变动。Christopher Missling与Steffen Thomas这两位关键人物,计划于2026年年度股东大会结束后正式退出董事会。这一决策标志着公司高层治理结构即将迎来新一轮调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVXL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183230552","title":"Anavex Life Sciences宣布董事会焕新计划,持续监督关键进展,力促股东价值创造","url":"https://stock-news.laohu8.com/highlight/detail?id=1183230552","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183230552?lang=zh_cn&edition=full","pubTime":"2026-08-03 20:01","pubTimestamp":1785758510,"startTime":"0","endTime":"0","summary":"Anavex Life Sciences Corp.正式对外披露,公司计划对董事会进行战略性更新。此举旨在确保其能够继续有效监督各项关键业务的推进,并致力于为股东创造更为丰厚的价值回报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVXL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159546917","title":"Anavex生命科学董事会任命前临床开发高级副总裁Terrie Kellmeyer博士为临时首席执行官","url":"https://stock-news.laohu8.com/highlight/detail?id=1159546917","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159546917?lang=zh_cn&edition=full","pubTime":"2026-05-06 19:01","pubTimestamp":1778065298,"startTime":"0","endTime":"0","summary":"Anavex生命科学公司(Anavex Life Sciences Corp.)董事会宣布一项重要人事任命:公司前临床开发高级副总裁Terrie Kellmeyer博士已被任命为临时首席执行官。\n此项任命标志着公司在领导层过渡期间,将依靠Kellmeyer博士在临床开发领域的深厚专业知识来指导公司战略。Kellmeyer博士此前在Anavex担任高级副总裁期间,在推动公司临床项目方面发挥了关键作用。\n董事会相信,凭借其丰富的经验和对公司研发管线的深刻理解,Kellmeyer博士将能有效领导公司度过这一时期,并确保核心业务运营的连续性与稳定性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVXL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518743902","title":"Anavex Life Sciences Corp.盘中异动 临近午盘股价大涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518743902","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518743902?lang=zh_cn&edition=full","pubTime":"2025-03-10 23:37","pubTimestamp":1741621049,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日23时37分,Anavex Life Sciences Corp.股票出现异动,股价急速上涨5.07%。截至发稿,该股报9.11美元/股,成交量29.0493万股,换手率0.34%,振幅7.84%。Anavex Life Sciences Corp.股票所在的生物技术行业中,整体涨幅为0.59%。Anavex Life Sciences Corp.公司简介:Anavex Life Sciences Corp 是一家临床阶段的生物制药公司,致力于通过精准医疗开发针对中枢神经系统疾病的差异化治疗药物,这些疾病存在高度未满足的需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310233730a26a53ed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310233730a26a53ed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AVXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516860630","title":"Anavex Life Sciences Corp.盘中异动 急速拉升5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516860630","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516860630?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:15","pubTimestamp":1741014921,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时15分,Anavex Life Sciences Corp.股票出现波动,股价急速拉升5.12%。截至发稿,该股报8.32美元/股,成交量17.146万股,换手率0.20%,振幅4.68%。Anavex Life Sciences Corp.股票所在的生物技术行业中,整体跌幅为0.09%。Anavex Life Sciences Corp.公司简介:Anavex Life Sciences Corp 是一家临床阶段的生物制药公司,致力于通过精准医疗开发针对中枢神经系统疾病的差异化治疗药物,这些疾病存在高度未满足的需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303231521abe6419d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303231521abe6419d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AVXL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512169464","title":"Anavex Life Sciences Corp.盘中异动 股价大涨5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512169464","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512169464?lang=zh_cn&edition=full","pubTime":"2025-02-18 23:14","pubTimestamp":1739891677,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日23时14分,Anavex Life Sciences Corp.股票出现异动,股价急速上涨5.05%。截至发稿,该股报8.95美元/股,成交量14.6079万股,换手率0.17%,振幅4.58%。Anavex Life Sciences Corp.股票所在的生物技术行业中,整体涨幅为0.84%。Anavex Life Sciences Corp.公司简介:Anavex Life Sciences Corp 是一家临床阶段的生物制药公司,致力于通过精准医疗开发针对中枢神经系统疾病的差异化治疗药物,这些疾病存在高度未满足的需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218231437a24ab690&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218231437a24ab690&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AVXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511748699","title":"Anavex Life Sciences Corp.盘中异动 股价大涨5.37%报8.93美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511748699","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511748699?lang=zh_cn&edition=full","pubTime":"2025-02-14 22:48","pubTimestamp":1739544527,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日22时48分,Anavex Life Sciences Corp.股票出现异动,股价快速拉升5.37%。截至发稿,该股报8.93美元/股,成交量6.3362万股,换手率0.07%,振幅5.19%。Anavex Life Sciences Corp.股票所在的生物技术行业中,整体涨幅为0.30%。Anavex Life Sciences Corp.公司简介:Anavex Life Sciences Corp 是一家临床阶段的生物制药公司,致力于通过精准医疗开发针对中枢神经系统疾病的差异化治疗药物,这些疾病存在高度未满足的需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214224847abcf0a89&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214224847abcf0a89&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AVXL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169314471","title":"Anavex生命科学公司2025年第一季度GAAP每股收益$(0.14)好于预期$(0.19),截至2024年12月31日公司现金及现金等价物为1.208亿美元,按当前现金使用率和范围预计可维持约4年","url":"https://stock-news.laohu8.com/highlight/detail?id=1169314471","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169314471?lang=zh_cn&edition=full","pubTime":"2025-02-12 20:56","pubTimestamp":1739364973,"startTime":"0","endTime":"0","summary":"Anavex生命科学公司报告季度亏损为每股$,好于分析师预期的每股$,超出26.32%。这一结果较去年同期每股亏损$下降了27.27%。以上内容来自Benzinga Earnings专栏,原文如下:Anavex Life Sciences reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 26.32 percent. This is a 27.27 percent decrease over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Anavex生命科学公司2025年第一季度GAAP每股收益$(0.14)好于预期$(0.19),截至2024年12月31日公司现金及现金等价物为1.208亿美元,按当前现金使用率和范围预计可维持约4年","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510132376","title":"Anavex Life Sciences(AVXL.US):2025年Q1财报实现营收0美元,前值为0美元;每股收益为-0.14美元,前值为-0.11美元,预期值为-0.17美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2510132376","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510132376?lang=zh_cn&edition=full","pubTime":"2025-02-12 20:44","pubTimestamp":1739364291,"startTime":"0","endTime":"0","summary":"Anavex Life Sciences(AVXL.US):2025年Q1财报实现营收0美元,前值为0美元;每股收益为-0.14美元,前值为-0.11美元,预期值为-0.17美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/12204448120548.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["AVXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510498333","title":"Anavex Life Sciences Corp.盘中异动 股价大跌5.03%报8.37美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510498333","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510498333?lang=zh_cn&edition=full","pubTime":"2025-02-11 23:09","pubTimestamp":1739286556,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日23时09分,Anavex Life Sciences Corp.股票出现波动,股价急速跳水5.03%。截至发稿,该股报8.37美元/股,成交量14.9578万股,换手率0.18%,振幅3.69%。Anavex Life Sciences Corp.股票所在的生物技术行业中,整体跌幅为1.56%。Anavex Life Sciences Corp.公司简介:Anavex Life Sciences Corp 是一家临床阶段的生物制药公司,致力于通过精准医疗开发针对中枢神经系统疾病的差异化治疗药物,这些疾病存在高度未满足的需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112309179881c461&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112309179881c461&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AVXL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508468718","title":"Anavex Life Sciences Corp.盘中异动 早盘急速上涨5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508468718","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508468718?lang=zh_cn&edition=full","pubTime":"2025-02-04 23:07","pubTimestamp":1738681663,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日23时07分,Anavex Life Sciences Corp.股票出现异动,股价快速拉升5.09%。Anavex Life Sciences Corp.股票所在的生物技术行业中,整体涨幅为1.01%。Anavex Life Sciences Corp.公司简介:Anavex Life Sciences Corp 是一家临床阶段的生物制药公司,致力于通过精准医疗开发针对中枢神经系统疾病的差异化治疗药物,这些疾病存在高度未满足的需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204230743a2393058&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204230743a2393058&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AVXL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508149313","title":"Anavex Life Sciences Corp.盘中异动 急速下挫5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508149313","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508149313?lang=zh_cn&edition=full","pubTime":"2025-02-03 22:31","pubTimestamp":1738593111,"startTime":"0","endTime":"0","summary":"北京时间2025年02月03日22时31分,Anavex Life Sciences Corp.股票出现波动,股价快速下挫5.18%。Anavex Life Sciences Corp.股票所在的生物技术行业中,整体跌幅为0.29%。Anavex Life Sciences Corp.公司简介:Anavex Life Sciences Corp 是一家临床阶段的生物制药公司,致力于通过精准医疗开发针对中枢神经系统疾病的差异化治疗药物,这些疾病存在高度未满足的需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502032231519616fb57&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502032231519616fb57&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AVXL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508174999","title":"Anavex Life Sciences Corp.盘中异动 股价大跌5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508174999","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508174999?lang=zh_cn&edition=full","pubTime":"2025-02-01 03:07","pubTimestamp":1738350422,"startTime":"0","endTime":"0","summary":"北京时间2025年02月01日03时07分,Anavex Life Sciences Corp.股票出现异动,股价大幅下挫5.12%。截至发稿,该股报9.08美元/股,成交量97.6056万股,换手率1.15%,振幅6.23%。Anavex Life Sciences Corp.股票所在的生物技术行业中,整体涨幅为0.62%。Anavex Life Sciences Corp.公司简介:Anavex Life Sciences Corp 是一家临床阶段的生物制药公司,致力于通过精准医疗开发针对中枢神经系统疾病的差异化治疗药物,这些疾病存在高度未满足的需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020103070296150aff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020103070296150aff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AVXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2506308410","title":"Anavex Life Sciences Corp.盘中异动 早盘快速跳水5.19%报9.95美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2506308410","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2506308410?lang=zh_cn&edition=full","pubTime":"2025-01-27 22:32","pubTimestamp":1737988332,"startTime":"0","endTime":"0","summary":"北京时间2025年01月27日22时32分,Anavex Life Sciences Corp.股票出现波动,股价急速下挫5.19%。截至发稿,该股报9.95美元/股,成交量6.024万股,换手率0.07%,振幅2.76%。Anavex Life Sciences Corp.股票所在的生物技术行业中,整体涨幅为0.02%。Anavex Life Sciences Corp.公司简介:Anavex Life Sciences Corp 是一家临床阶段的生物制药公司,致力于通过精准医疗开发针对中枢神经系统疾病的差异化治疗药物,这些疾病存在高度未满足的需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025012722321296123961&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025012722321296123961&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AVXL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2506521867","title":"Anavex Life Sciences Corp.盘中异动 股价大涨5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2506521867","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2506521867?lang=zh_cn&edition=full","pubTime":"2025-01-24 23:46","pubTimestamp":1737733608,"startTime":"0","endTime":"0","summary":"北京时间2025年01月24日23时46分,Anavex Life Sciences Corp.股票出现异动,股价大幅拉升5.06%。截至发稿,该股报10.72美元/股,成交量24.1811万股,换手率0.29%,振幅6.72%。Anavex Life Sciences Corp.股票所在的生物技术行业中,整体跌幅为0.39%。Anavex Life Sciences Corp.公司简介:Anavex Life Sciences Corp 是一家临床阶段的生物制药公司,致力于通过精准医疗开发针对中枢神经系统疾病的差异化治疗药物,这些疾病存在高度未满足的需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250124234648abb7607e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250124234648abb7607e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AVXL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.anavex.com","stockEarnings":[{"period":"1week","weight":-0.0445},{"period":"1month","weight":-0.2107},{"period":"3month","weight":-0.0853},{"period":"6month","weight":-0.2107},{"period":"1year","weight":-0.7272},{"period":"ytd","weight":-0.3371}],"compareEarnings":[{"period":"1week","weight":-0.0119},{"period":"1month","weight":-0.0067},{"period":"3month","weight":0.0247},{"period":"6month","weight":0.1652},{"period":"1year","weight":0.1515},{"period":"ytd","weight":0.1207}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Anavex Life Sciences Corp.成立于2004年1月23日,位于内华达州。是一家临床阶段的生物制药公司,致力于开发差异化疗法,将精准医学应用于高度未满足需求的中枢神经系统(CNS)疾病。该公司的重点是开发针对阿尔茨海默病、帕金森病、精神分裂症、神经发育、神经退行性疾病、包括雷特综合征在内的罕见疾病以及其他中枢神经系统(CNS)疾病的创新疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":-0.012212},{"month":2,"riseRate":0.454545,"avgChangeRate":0.117029},{"month":3,"riseRate":0.545455,"avgChangeRate":0.041572},{"month":4,"riseRate":0.363636,"avgChangeRate":-0.058062},{"month":5,"riseRate":0.636364,"avgChangeRate":0.022465},{"month":6,"riseRate":0.636364,"avgChangeRate":0.14039},{"month":7,"riseRate":0.545455,"avgChangeRate":-0.021632},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.03176},{"month":9,"riseRate":0.454545,"avgChangeRate":-0.004809},{"month":10,"riseRate":0.5,"avgChangeRate":-0.003565},{"month":11,"riseRate":0.363636,"avgChangeRate":-0.028939},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.025909}],"exchange":"NASDAQ","name":"Anavex Life Sciences Corp.","nameEN":"Anavex Life Sciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Anavex Life Sciences Corp.(AVXL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Anavex Life Sciences Corp.(AVXL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Anavex Life Sciences Corp.,AVXL,Anavex Life Sciences Corp.股票,Anavex Life Sciences Corp.股票老虎,Anavex Life Sciences Corp.股票老虎国际,Anavex Life Sciences Corp.行情,Anavex Life Sciences Corp.股票行情,Anavex Life Sciences Corp.股价,Anavex Life Sciences Corp.股市,Anavex Life Sciences Corp.股票价格,Anavex Life Sciences Corp.股票交易,Anavex Life Sciences Corp.股票购买,Anavex Life Sciences Corp.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Anavex Life Sciences Corp.(AVXL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Anavex Life Sciences Corp.(AVXL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}